Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI 48824-1226, USA.
FEBS J. 2010 Dec;277(23):4806-13. doi: 10.1111/j.1742-4658.2010.07903.x.
The discovery of RNA interference (RNAi) generated considerable interest in developing short interfering RNAs (siRNAs) for understanding basic biology and as the active agents in a new variety of therapeutics. Early studies showed that selecting an active siRNA was not as straightforward as simply picking a sequence on the target mRNA and synthesizing the siRNA complementary to that sequence. As interest in applying RNAi has increased, the methods for identifying active siRNA sequences have evolved from focusing on the simplicity of synthesis and purification, to identifying preferred target sequences and secondary structures, to predicting the thermodynamic stability of the siRNA. As more specific details of the RNAi mechanism have been defined, these have been incorporated into more complex siRNA selection algorithms, increasing the reliability of selecting active siRNAs against a single target. Ultimately, design of the best siRNA therapeutics will require design of the siRNA itself, in addition to design of the vehicle and other components necessary for it to function in vivo. In this minireview, we summarize the evolution of siRNA selection techniques with a particular focus on one issue of current importance to the field, how best to identify those siRNA sequences likely to have high activity. Approaches to designing active siRNAs through chemical and structural modifications will also be highlighted. As the understanding of how to control the activity and specificity of siRNAs improves, the potential utility of siRNAs as human therapeutics will concomitantly grow.
RNA 干扰 (RNAi) 的发现引起了人们极大的兴趣,促使人们开发短干扰 RNA (siRNA),以用于理解基础生物学,并作为各种新型治疗药物的有效因子。早期研究表明,选择有效的 siRNA 并不像简单地在靶 mRNA 上选择一个序列并合成与该序列互补的 siRNA 那样简单。随着对 RNAi 的应用兴趣的增加,鉴定有效 siRNA 序列的方法已经从关注合成和纯化的简单性,发展到鉴定首选的靶序列和二级结构,再到预测 siRNA 的热力学稳定性。随着 RNAi 机制的更多具体细节被定义,这些细节被整合到更复杂的 siRNA 选择算法中,从而提高了针对单个靶标选择有效 siRNA 的可靠性。最终,设计最佳的 siRNA 治疗药物除了需要设计 siRNA 本身之外,还需要设计载体和其他必要的组件,使其在体内发挥作用。在这篇综述中,我们总结了 siRNA 选择技术的演变,特别关注当前该领域的一个重要问题,即如何最好地识别那些可能具有高活性的 siRNA 序列。通过化学和结构修饰设计有效 siRNA 的方法也将被强调。随着人们对如何控制 siRNA 的活性和特异性的理解的提高,siRNA 作为人类治疗药物的潜力也将相应地增加。